scorecardresearch
Wednesday, August 27, 2025
TopicCovaxin

Topic: Covaxin

Science ministry says Covid vaccine ‘unlikely’ before 2021, then drops claim in new statement

Science ministry statement refers to India’s two indigenous vaccines that will enter human trial stage — ICMR-backed Covaxin by Bharat Biotech and Zydus Cadila's ZyCov-D.

‘Meant to cut red-tape, not scientific rigour’ — ICMR defends bid to fast-track Covid vaccine

Referring to the row over vaccine release date, ICMR says the best of India’s medical professionals & research scientists should not be second-guessed for their professionalism.

PM Modi chairs high-level meeting, reviews preparations for Covid vaccination

In the meet, PM said affordable and universal Covid vaccination should be ensured and vulnerable groups identified and prioritised.

On Camera

India will absorb Trump tariff impact due to its Achilles’ heel

Like China, India remains a big domestic market, which will continue to attract investment, but the US tariffs will make India unattractive for future investments.

New insolvency frameworks to shorter timelines, how 2025 amendment bill proposes to transform IBC

New bill aims to fix key issues with IBC 2016, including delays & patchy implementation, and protect creditors, with window for genuine promoters to retain control of their companies.

Op Sindoor lesson: IAF chief bats for joint planning & coordination centre in Delhi, not theaterisation

Contrary to claims regarding implementation of theaterisation, ThePrint first reported on 17 June 2021 that it will be delayed. Now, ACM Singh bats for different structure.

That Oval Office picture for ages deserves closer Indian reading, with a geopolitical lens

Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.